DCAF15 Inhibitors

Chemical inhibitors of DCAF15 can exert their inhibitory effects by engaging with the cereblon-DDB1-DCAF15 E3 ubiquitin ligase complex, which is crucial for the ubiquitination and subsequent degradation of various proteins. Lenalidomide, Pomalidomide, Thalidomide, Avadomide, Iberdomide, CC-885, and CC-90009 are such chemical inhibitors that can bind to cereblon, a key component of the E3 ligase complex. This binding can disrupt the normal function of the complex, thereby inhibiting the E3 ligase activity of DCAF15. Specifically, these chemicals can prevent the recognition and binding of substrate proteins to the complex, or they can obstruct the complex's ability to ubiquitinate these substrates. The inhibition of this ubiquitination process is crucial as it directly impairs the functional activity of DCAF15, whose role is to target certain proteins for proteasomal degradation.

Furthermore, other chemical inhibitors like SGC-CBP30, A-485, and MG149 target histone acetyltransferases such as CBP/p300 and TIP60. These enzymes are responsible for the acetylation of histones and other proteins, which can influence the expression of genes, including those that encode for substrates of DCAF15. By inhibiting these histone acetyltransferases, the chemicals can alter the acetylation status of proteins, potentially leading to changes in the protein levels or their susceptibility to ubiquitination by DCAF15. For example, a protein that is not properly acetylated might not be recognized or ubiquitinated by DCAF15, resulting in inhibition of the role DCAF15 plays in protein degradation. This indirect inhibition mechanism affects the functional activity of DCAF15 by altering the post-translational modifications of its substrates, thereby impacting the protein's ability to carry out its normal cellular functions.